je.st
news
Tag: pharmaceuticals
Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA(TM) in Pheochromocytoma
2015-01-23 18:05:55| Biotech - Topix.net
Progenics Pharmaceuticals, Inc., announced today that it has dosed the first subject in the resumed pivotal Phase 2 clinical study of Azedra in patients with malignant pheochromocytoma and paraganglioma. The trial is being conducted under a Special Protocol Assessment with the U.S. Food and Drug Administration .
Tags: trial
pharmaceuticals
pivotal
relaunches
Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubists 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020
2015-01-22 21:29:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced that, in connection with the completion of the acquisition of Cubist by Merck, Cubist has commenced a tender offer (the Convertible Notes Tender Offer) to repurchase, at the option of each holder, any and all of its outstanding 2.50% Convertible Senior Notes due 2017 (the 2017 Convertible Notes), 1.125% Convertible Senior Notes due 2018 (the
Cipher Pharmaceuticals appoints Lynne Bulger as Vice President, Medical Affairs
2015-01-19 14:51:21| Biotech - Topix.net
Ms. Bulger has 27 years of experience in drug development in the pharmaceutical industry, conducting clinical research and providing strategic medical marketing support in dermatology, rheumatology, osteoporosis and CNS. Most recently, Ms.
Tags: medical
president
vice
vice president
High Alpha In Shorting Infinity Pharmaceuticals With Potential Failure Of Upcoming Trials
2015-01-10 22:41:32| Biotech - Topix.net
Although Infinity has a collaboration agreement with AbbVie for IPI-145 in blood malignancies, I have doubts about the potential of the selective PI3K inhibitor following the failure in RA. If IPI-145 also fails in blood malignancies then Infinity is effectively worth only the cash on its balance sheet.
Tags: high
potential
failure
alpha
Short AMAG Pharmaceuticals After Poor Acquisition
2015-01-10 18:21:57| Biotech - Topix.net
AMAG Pharmaceuticals , formerly known as Advanced Magnetics, was a high-flying biotech stock in the mid-2000s, with a peak share price of $71.45 in late 2006. The company had elicited widespread investor interest in its novel IV iron product , with the strategy of achieving a very broad-label indication for iron-deficient anemia by running a very comprehensive series of clinical trials involving nearly 2,000 patients.
Tags: short
poor
acquisition
pharmaceuticals
Sites : [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] next »